Two preferred regimens for treating multiple myeloma patients have been recommended for those not eligible for stem cell transplant. A recent study found that triple therapy with daratumumab, lenalidomide, and dexamethasone led to significantly longer time to next treatment or death than the alternative triple regimen containing bortezomib. These findings are based on a real-world data analysis. Patients who received daratumumab had a 42% lower risk of death or time to next treatment, compared to those who received bortezomib, according to the study. The researchers concluded that daratumumab combination is a superior treatment for newly diagnosed, transplant-ineligible multiple myeloma patients. The study was supported by Janssen.
Source link
This Frontline Therapy Is Better in Multiple Myeloma: Study
